




Patent Docket P1096R1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

GP 1635
#7
JF
7/21/99
w/cont

| | |
|--|--|
| In re Application of: T. Shantha Raju Serial No.: 09/102,865 Filed: 23 June 1998 For: METHODS AND COMPOSITIONS FOR GALACTOSYLATED GLYCOPROTEINS | Group Art Unit: 1635 Examiner: To Be Assigned CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on July 2, 1999  Janet Tse |
|--|--|

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

In accordance with the duty imposed by 37 CFR §1.56 to disclose to the Patent Office information coming to the attention of each individual associated with the filing or prosecution of the subject application which may be material to the patentability of any claim of the application, Applicants direct the Examiner's attention to the information listed on the attached Form 1449 (Modified). A copy of the items on the PTO-1449 (Modified) is supplied herewith.

This Information Disclosure Statement is filed before the mailing date of a first Office action on the merits. Should any fee be due, the U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 to cover the cost of this Information Disclosure Statement.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR §1.56, it is not intended to constitute an admission that any


RECEIVED
JUL 13 1999
TC 1600 MAIL ROOM

patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR §1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR §1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR §1.98 and MPEP §609 and the Examiner is respectfully requested to consider the listed references.

Respectfully submitted,
GENENTECH, INC.

Date: 2 July 1999

By 
Jeffrey S. Rubinec
Reg. No. 36,575

1 DNA Way
So. San Francisco, CA 94080-4990
Phone: (650) 225-8228
Fax: (650) 952-9881

RECEIVED
JUL 13 1999
TC 1600 MAIL ROOM